戻る Agenda
[V8-S6] For Providing the Most Appropriate Medicine - The Current State of Use and Development of Companion Diagnostics (Mainly on Next Generation Sequencers)
Session Chair(s)
Kazuto Nishio, MD
Professor
Kindai University Faculty of Medicine, Japan
The existence of companion diagnostics is important for delivering medicine suitable for each patient. Genomic analysis is performed using next generation sequencer in cancer genome medical treatment, and genomic mutation for each patient and cell is revealed. In this session, present current status of “Precision Medicine” using Next Generation Sequencer, Issues in using next-generation sequencers, and issues of companion diagnostic drug development from the standpoint of each industry, government and academia. And also discuss the solution on panel-discussion.
Speaker(s)
Regulatory Perspectives on NGS-based CDx
Reiko Yanagihara, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Deputy Review Director, Office of In Vitro Diagnostics
NGS-Based Clinical Sequencing System for Precision Cancer Medicine in Japan
Takashi Kohno, PhD
National Cancer Center Research Institute, Japan
Division of Genome Biology
Issue on the Development of CoDxs from Diagnostics Company’s Points of View
Miwa Nishida
Roche Diagnostics K.K., Japan
Regulatory affairs
Development of NGS- based CDx from a Pharmaceutical Company’s Viewpoint
Michio Tanaka
AstraZeneca K.K., Japan
Executive Officer, Division Vice president, Science & Data Technology Division